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The ligand binding function of integrins can be mod-
ulated by various monoclonal antibodies by both direct
and indirect mechanisms. We have characterized an an-
ti-1 antibody, SG/19, that had been reported to inhibit
the function of the 1 integrin on the cell surface. SG/19
recognized the wild type 1 subunit that exists in a con-
formational equilibrium between the high and low affin-
ity states but bound poorly to a mutant 1 integrin that
had been locked in a high affinity state. Epitope map-
ping of SG/19 revealed that Thr82 in the 1 subunit, lo-
cated at the outer face of the boundary between the
I-like and hybrid domains, was the key binding determi-
nant for this antibody. Direct visualization of the 51
headpiece fragment in complex with SG/19 Fab with
electron microscopy confirmed the location of the bind-
ing surface and showed that the ligand binding site is
not occluded by the bound Fab. Surface plasmon reso-
nance showed that 51 integrin bound by SG/19 main-
tained a low affinity toward its physiological ligand fi-
bronectin (Fn) whereas binding by function-blocking
anti-5 antibodies resulted in a complete loss of fi-
bronectin binding. Thus a class of the anti- antibodies
represented by SG/19 attenuate the ligand binding func-
tion by restricting the conformational shift to the high
affinity state involving the swing-out of the hybrid do-
main without directly interfering with ligand docking.
Integrins are cell adhesion molecules that bind to ligands in
the extracellular matrix and on cell surfaces and regulate
many biological functions including cell migration. The affinity
of integrins for ligands is conformationally regulated (1–4). On
physiological cell surfaces, integrins can assume multiple con-
formations with distinct affinity states, with the low affinity
state being predominant. Physiological “inside-out” signals
that impinge on integrin cytoplasmic domains and activating or
inhibitory mAbs1 that bind to the integrin extracellular domain
are thought to alter the equilibrium between different confor-
mational states. Electron microscopic (EM) studies of the ex-
tracellular domain, fluorescence resonance energy transfer and
NMR studies on the cytoplasmic domains, and disulfide cross-
linking of the transmembrane domains have indicated that
close apposition of the membrane-proximal region of each sub-
unit and the overall bent structure are hallmarks for the low
affinity state of integrins, whereas the extended conformation
with separated legs represents the high affinity state (5–8).
Monoclonal antibodies have been instrumental to studies on
the structure and function of integrins (9). Integrin mAbs can
be divided into three classes: (i) “inhibitory mAbs” that perturb
biological function i.e. ligand binding, (ii) “stimulatory mAbs”
that augment ligand binding, and (iii) “neutral mAbs” that do
not have any impact on activity. Although some inhibitory
mAbs directly recognize the ligand binding site on the integrin
molecule and act as ligand-mimetic competitive inhibitors, an-
other class of inhibitory mAbs bind outside the ligand binding
site and seem to inhibit integrin function allosterically (10, 11).
It is assumed that this class of mAbs exert their effect by
stabilizing the unoccupied state of the receptor or by prevent-
ing a conformational change necessary for ligand occupancy, in
a manner opposite from that of stimulating mAbs (12). How-
ever, the mechanism by which these mAbs affect the conforma-
tional change in integrins has not been determined nor has the
effect of these mAbs on the ligand binding kinetics of integrins
been investigated. Here we present direct evidence that a class
of allosteric anti-1 mAbs, represented by SG/19, binds distal to
the ligand binding site across the interface between the I-like
and hybrid domains of the 1 subunit and prevents intercon-
version of the receptor conformation by blocking the hybrid
domain swing-out. The restriction imposed by mAb binding
maintains the integrin in a low, but not zero, affinity state.
EXPERIMENTAL PROCEDURES
Monoclonal Antibodies—The murine anti-human 1 mAbs SG/19
(IgG1) and SG/7 (IgA) were kindly provided by Dr. K. Miyake (13).
Murine anti-human 1 mAbs TS2/16 (14), K20 (15), rat anti-human 5
mAbs 16 (16), 11 (17), and rat anti-human 1 mAb 13 (16) were obtained
from the Fifth International Leukocyte Workshop (18). Murine anti-1
mAbs JB1 (19), 12G10 (20), HUTS-4 (21), and 5 mAb P1D6 (22) were
purchased from Chemicon International Inc. (Temecula, CA). The Fab
fragment of SG/19 IgG was prepared as described previously (23).
Transfection and mAb Binding—Plasmids coding for full-length wild
type or G429N mutant human 1 were subcloned into pEF1/V5-HisA
and introduced into the CHO-K1 cells using calcium phosphate precip-
itation. After selecting the transfected cells in a medium containing 1
mg/ml Geneticin G418 for 1 week, the surviving cells were sorted by
fluorescence-activated cell sorting to obtain cell lines expressing the
desired level of human 1 integrins. For epitope mapping, CHO-K1 cells
transfected with a human 1 chain carrying single point mutation were
cultured in a medium containing 1 mg/ml Geneticin G418 for 2 weeks,
and the surviving cell population was tested for reactivity against
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various mAbs without further cloning. Bindings of mAbs were evalu-
ated by fluorescence-activated cell sorting analysis using either anti-
mouse or anti-rat IgG conjugated with fluorescein isothiocyanate. Fi-
bronectin binding was evaluated by incubating human 1-expressing
cells with 50 g/ml bovine plasma fibronectin labeled with fluorescein
isothiocyanate in the presence or absence of activating mAb TS2/16 (10
g/ml) at room temperature for 30 min followed by flow cytometric
analysis.
Negative Stain EM of 51 Head Fragment—A soluble 51 head-
piece fragment containing 5 residues 1–623 and 1 residues 1–445 was
produced and purified as described previously (24). The construct con-
tained a disulfide-bonded C-terminal “clasp,” which was removed spe-
cifically by tobacco etch virus protease treatment prior to the analysis.
Unclasped 51 fragment was incubated with a saturating concentra-
tion of SG/19 Fab fragment or Fn7–10 fragment and purified on a
Superdex 200 HR column equilibrated with 50 mM Tris HCl, pH 7.5, 150
mM NaCl, containing 1 mM MnCl2. The peak fraction was adsorbed to
glow-discharged carbon-coated copper grids, stained with uranyl for-
mate, and inspected with an FEI Tecnai 12 electron microscope oper-
ated at 120 kV. Image processing was performed using the SPIDER
image processing package (25) as described previously (24).
Surface Plasmon Resonance (SPR) Binding Assay—Interaction be-
tween the recombinant full-length 51 and recombinant fibronectin
fragment was assessed by SPR analysis with a BIAcore 3000 (Biacore
AB) as described previously (26). Briefly, 1.7 g of 51 was incubated
with 4.2 g of purified IgG for 30 min in Tris-buffered saline contain-
ing 1 mM MnCl2, diluted to give a final concentration of 20–40 nM, and
flowed at 20 l/min at 25 °C over a streptavidin-coated sensor chip
immobilized with biotinylated Fn7–10 at a density of 500 resonance
units. All measurements were base line-corrected by subtracting the
sensorgram obtained with a control streptavidin surface, and kinetic
parameters were determined by fitting the data to a 1:1 Langmuir
binding model using BIAevaluation software version 3.0.
RESULTS
The SG/19 Epitope Maps to Thr82 in the Hybrid Domain of
the 1 Subunit—SG/19 was originally identified as a mouse
mAb that blocked binding of the Nalm-6 human pre-B cell line
to the murine stromal cell line BMS2 (13). It strongly inhibits
1 integrin-mediated cell adhesion at 10 g/ml (13). Whereas
most function-blocking mAb to 1 bind to the I-like domain (9,
27), SG/19 maps to a more N-terminal region in the 1 subunit
(28). Within this N-terminal region, only 4 residues in the PSI
domain and 7 residues in the hybrid domain differ between
human and mouse 1. Although these domains are not known
to be implicated in the ligand binding function, inspection of a
homology model of 51 reveals that 2 of these 11 species-
specific residues (i.e. Thr82 and Lys87) are positioned very close
to the ligand binding I-like domain (Fig. 1) and thus are likely
candidates for the SG/19 epitope. These residues were individ-
ually mutated to the corresponding murine residue, and the
reactivity of SG/19 was evaluated. As shown in Table I, the
binding of SG/19 to the 1 chain was critically dependent on
Thr82, whereas the mutation at Lys87 did not affect the binding.
Conversely, the binding of another function-blocking mAb,
SG/7, which had been reported to recognize a Ca2-dependent
epitope (29) was totally abolished by the mutation of Lys87 and
only partially by the mutation of Thr82. Mutation of species-
specific residues in the I-like domain, i.e. N207D, K208R,
V211F, K218Q, M287V, and A342G, did not affect the binding
of either mAb.
Rat anti-human 1 mAb 13 has been characterized exten-
sively and reported to block human 1 integrin function by an
allosteric mechanism (11). The epitope for mAb 13 had been
mapped to residues 207–218 in the 1 I-like domain (27). Our
results revealed that mAb 13 recognizes a combinatorial
epitope made by Asn207, Lys208, and Val211 with Asn207 con-
tributing the most (Table I). Next we explored whether SG/19
and mAb 13 compete with each other for binding to 1. Cy3-
labeled SG/19 was competed out by mAb 13 for binding to wild
type human 1 (Table II). Reciprocally, the binding of mAb 13
was competed by mAb SG/19. Reciprocal competition was also
observed between SG/19 and SG/7 mAbs (data not shown) and
between mAb SG/7 and mAb 13 (13). In contrast, SG/19 did not
compete with two other mAbs, TS2/16 and 4B4, mapped to
residues 207–218 (data not shown) indicating that the binding
site for mAb 13 is slightly different from that for TS2/16 and
4B4. In the three-dimensional model, Asn207, Thr82, and Lys87
are all located in close proximity (Fig. 1B). Because the anti-
gen-binding footprints for the three inhibitory mAbs 13, SG/19,
and SG/7 are overlapping, they are likely to have similar im-
pacts on the conformation of the junction of the 1 I-like and
hybrid domains to which they bind.
Inhibitory mAbs Show Diminished Binding toward Mutant
1 Integrin Locked in a High Affinity State—Stimulatory
mAbs, upon binding to integrins, shift the conformational equi-
librium toward the active conformer. Therefore, stimulatory
mAbs generally show increased binding toward activated re-
ceptors (9, 23, 30). Allosteric inhibitory mAbs that work in the
opposite way are expected to show reduced binding to the active
conformer. We have successfully engineered a mutant 3 inte-
grin constitutively in a high affinity state by introducing an
N-glycosylation site, i.e. a glycan wedge, at the inner side of the
bend between the I-like and hybrid domains (31). A previously
designed 1 glycan wedge mutant, 1-P333N, has a high affin-
FIG. 1. Three-dimensional model of the 51 integrin headpiece. A model of the 51 headpiece fragment comprising the 5 -propeller and
the thigh domain (both in gray) and the 1 I-like (magenta) and hybrid (cyan) domains was built using the closed V3 structure (PDB code 1JV2)
as a template by SWISS-MODEL (37). The location of the PSI domain, which is not seen in the crystal structure, is shown as a purple sphere. A–C,
CPK presentations viewed from three different directions rotated by 90° about the vertical axis. 1 residues that differ between human and mouse
are painted green with key residues labeled. The position of the activating mutation G429N is also labeled in red. Putative binding footprints for
inhibitory mAbs 13, SG/19, and SG/7 are marked by a black, red, and blue dotted oval, respectively.
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ity for ligands (31), although it is less well expressed than wild
type and only partially expresses activation epitopes. There-
fore, another mutant, 1-G429N, was designed to introduce an
N-glycosylation site at Asn429 to wedge open the I-like hybrid
domain interface (Fig. 1C). This mutant shows maximal ligand
binding activity in the absence of any activating agents (Fig.
2A). This activated 1 mutant assumes the high affinity con-
formation in the absence of a bound ligand, as shown by the
markedly increased binding of the stimulatory mAbs 12G10
and HUTS-4 compared with binding to the wild type receptor
(Fig. 2B). Conversely, binding of the inhibitory mAbs 13 and
SG/19 was decreased more than 4-fold to the 1-G429N mutant
compared with wild type (Fig. 2B). SG/7 also reacted much less
well (70% reduction from wild type) to the wedge mutant
(data not shown). A reduction of mAb 13 binding and augmen-
tation of mAb HUTS-4 by an activating mutation in the 1
I-like domain 7-helix has been reported (32). These effects of
the L358A mutation are much less pronounced (50% reduc-
tion and 50% increase in binding of mAbs 13 and HUTS-4,
respectively) than the G429N mutation. As Gly429 is located far
from the SG/19 epitope at Thr82 and the mAb 13 epitope at
Asn207 (Fig. 1), it is unlikely that mutation of Gly429 directly
affects binding to these epitopes. Taken together, the data
suggest strongly that the inhibitory mAbs 13 and SG/19 prefer
the resting (i.e. low affinity) conformer and stabilize this con-
formation upon binding thereby allosterically modulating the
ligand binding activity of 1 integrin.
EM Images of SG/19 Fab Bound to the 51 Integrin Head-
piece—We next sought to clarify how SG/19 could stabilize a
particular conformation of an integrin. In a recent study (24),
we utilized negative stain EM and image analysis to visualize
a headpiece fragment of 51 integrin in the absence and pres-
ence of a bound ligand. In the absence of a bound ligand, the
51 headpiece assumes the “closed” conformation with the 1
hybrid domain close to the  subunit (Fig. 3A and Ref. 24).
Binding to a fragment of the ligand fibronectin changes the
conformation dramatically, with an outward swing of the hy-
brid domain away from the  subunit to assume the “open”
conformation (Fig. 3B and Ref. 24). The complex of the 51
headpiece and SG/19 Fab reveals a clear density for the Fab
bound to the side of the 1 subunit (Fig. 3C). The Fab fragment
can be easily distinguished by its typical oval shape with a
“dimple” corresponding to the thin central part between the
VL/VH and CL/CH1 lobes. The very uniform orientation of SG/19
Fab relative to the rest of the particle makes it possible to
define the binding surface. The antigen binding site of the
SG/19 Fab docks to the boundary between the I-like and hybrid
domains of the 1 subunit at the “side” away from the 5
subunit. This is in perfect agreement with the result of the
epitope mapping (see Fig. 1). Importantly, the ligand binding
interface located on the top of the receptor is completely ex-
posed and not occluded by the bound Fab (Fig. 3, compare B
TABLE I
Effect of single amino acid substitutions in the N-terminal region of the 1 chain on the reactivity of anti-1 mAbs
CHO-K1 transfectants expressing human 1 containing the indicated mutations were examined for reactivity with anti-1 mAbs by immuno-
fluorescence flow cytometry. 207/208/211 denotes 1 carrying the combined mutations N207D, K208R, and V211F. The numbers in the table
represent the percentages of positive cells in a typical experiment. /, /, and / represent positive, partial, and negative reactivities, respectively.
Wild type 1 T82M K87R N207D K208R V211F K218Q M287V A342G 207/208/211
Control 0.6/ 0.8/ 0.7/ 0.6/ 0.9/ 0.8/ 0.8/ 1.6/ 2.8/ 1.7/
K20 14.2/ 11.1/ 16.0/ 14.5/ 23.9/ 6.9/ 18.9/ 18.7/ 10.5/ 19.0/
SG/19 11.7/ 0.6/ 15.8/ 15.6/ 18.1/ 3.9/ 18.1/ 18.1/ 11.4/ 20.7/
SG/7 12.5/ 4.0/ 0.3/ 13.8/ 15.9/ 4.6/ 17.6/ 15.2/ 7.4/ 13.8/
13 13.9/ 17.2/ 19.6/ 6.2/ 19.2/ 3.8/ 19.2/ 19.6/ 11.2/ 1.5/
TS2/16 13.8/ 14.7/ 16.5/ 14.0/ 23.0/ 4.3/ 19.6/ 21.4/ 11.2/ 3.2/
TABLE II
Competitive binding between mAbs 13 and SG/19
CHO-K1 cells transfected with wild type human 1 were stained with
5 g/ml Cy3-labeled mAbs (or unlabeled rat mAb 13 in combination
with fluorescein isothiocyanate-anti-rat IgG) in the absence or presence
of 50 g/ml unlabeled antibodies. Binding is expressed as the back-
ground-subtracted mean fluorescence intensity as percent of control





None 100 100 100
K20 0 108 88
SG/19 93 0.8 14
13 97 2.8 NT
FIG. 2. Effect of an engineered activating mutation in 1 on the
binding of stimulating and inhibitory mAbs. A, The G429N muta-
tion constitutively activates 1 integrin. CHO-K1 cells expressing wild
type or mutant 1 integrin were incubated with 50 g/ml fluorescein
isothiocyanate-Fn in the presence (hatched bar) or absence (solid bar) of
10 g/ml anti-1 activating mAb TS2/16. Ligand bindings are expressed
as the mean fluorescence intensities of bound fluorescein isothiocya-
nate-Fn, after the subtraction of background binding obtained in the
presence of 5 mM EDTA, relative to that of non-functional anti-1 mAb
K20 staining to normalize the differences in the expression level. B,
CHO-K1 cells expressing wild type (solid bars) or G429N mutant
(hatched bars) 1 integrins were stained with non-functional (K20),
stimulatory (TS2/16, 12G10, HUTS-4), or inhibitory (13 and SG/19) 1
mAbs. The mean fluorescence intensities relative to that of K20 were
shown.
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with C). The images show that the binding site of SG/19 centers
on the junction between the I-like and hybrid domains, very
close to the location of the key antigenic residue Thr82, which is
at the domain boundary (see Fig. 1). The binding site of SG/19
clearly includes significant portions of both the I-like and hy-
brid domains (Fig. 3C). This binding site is significantly rear-
ranged when the hybrid domain swings out 70° upon binding
fibronectin (Fig. 3B) so that it is unlikely that SG/19 could bind
to it. These findings suggest that SG/19 prevents the outward
swing of the hybrid domain, trapping the integrin in a low
affinity conformation.
51 Bound by Inhibitory Anti-1 mAbs Has Low but Detect-
able Affinity for Ligands—The ligand binding characteristics of
51 integrin bound by inhibitory mAbs was measured using
SPR to determine whether these mAbs abolished ligand bind-
ing, or maintained 51 in a low affinity state. To ensure
saturation, purified recombinant 51 integrin was preincu-
bated with purified mAbs in large excess. Incubation with 1.8
M SG/19 Fab for 10 min resulted in saturation binding of the
51 headpiece with no dissociation detected during 20 min of
gel filtration (Fig. 3D). Saturation was also observed with 100
nM SG/19 Fab (not shown). Reaction mixtures containing 140
nM 51 headpiece and 560 nM mAb (i.e. 1120 nM of Fab equiv-
alents) were diluted up to 7-fold (thus maintaining the concen-
tration of uncomplexed Fab equivalents at 140 nM) and di-
rectly infused onto sensor chips coated with fibronectin
fragment in a buffer containing 1 mM Mn2. 51 complexed
with the non-blocking, non-activating 5 mAb 11 showed an
elevated signal compared with the uncomplexed 51 because
of the increased mass of the analyte (Fig. 4, compare tracing b
with c). Although mAb 11 binding slightly changed the binding
kinetics by decreasing the dissociation rate, this seems to be a
general effect of mAb binding, because another non-blocking,
non-activating 1 mAb JB1 (Fig. 4a) and an anti-coiled coil tag
mAb 2H11(not shown) had a similar effect. The inhibitory 5
mAbs 16 (Fig. 4g) and P1D6 (Fig. 4f) completely abolished the
binding of 51 headpiece to fibronectin. In contrast, 51 com-
plexed with mAb 13 (Fig. 4d) or SG/19 (Fig. 4e) showed de-
creased but significant binding to the ligand. Increasing the
mAb concentration 2-fold did not alter the binding (not shown).
Together with the saturation binding experiments described
above, the known KD of 0.34 nM of mAb 13 for 51 (11), and the
high concentrations of mAb used in SPR, these results demon-
strate that the incomplete inhibition is not because of incom-
plete saturation of the binding sites by mAbs. Therefore, mAbs
SG/19 and 13 decrease the affinity of 51 for fibronectin. The
kinetic constants (Table III) show that SG/19 binding affected
both association and dissociation rate constants resulting in an
overall 30-fold drop in the KD value.
DISCUSSION
Through EM visualization and binding kinetic measure-
ments, we present evidence that anti-1 inhibitory mAb SG/19
exerts its effect allosterically. The inhibitory mAbs 13 and SG/7
TABLE III
Kinetic parameters for 51 binding to Fn7–10 fragment
Surface plasmon resonance binding was performed as described un-
der “Experimental Procedures” and the kinetic parameters were de-
rived using the BIAsimulation software. Values are mean  S.E. ob-
tained from three different analyte concentrations.
Bound mAb kon koff KD
 105 M1 s1  103 s1 nM
None 4.5  0.2 5.5  0.3 12
11 4.5  0.4 2.3  0.3 5.1
SG/19 0.6  0.1 8.9  0.1 151
FIG. 3. Visualization of the 51 headpiece fragment in com-
plex with SG/19 Fab. Projection averages for 51 headpiece fragment
alone (A), in complex with the Fn7–10 fragment (B), or in complex with
SG/19 Fab (C) obtained by negative stain EM are shown. The most (A
and B) or three most (C) typical averages are shown, each containing
200–500 particles. Scale bars, 100 Å. In the far right of each panel,
schematic diagrams for the domain organization are also shown. D,
saturation of SG/19 Fab binding to the 51 head fragment. 5.4 g of
51 head fragment was incubated with (solid line) or without (dotted
line) a 2-fold molar excess concentration of SG/19 Fab for 10 min at
room temperature and subjected to gel filtration on Superdex 200 at a
flow rate of 0.5 ml/min. The elution positions for the 51 fragment and
its complex with Fab correspond to apparent molecular masses of 190
and 250 kDa, respectively.
FIG. 4. Surface plasmon resonance binding analysis of recom-
binant 51 to Fn7–10. Biotinylated Fn7–10 (500 resonance units)
was immobilized onto a streptavidin-coated chip. Complexes between
full-length recombinant 51 and mAbs prepared as described under
“Experimental Procedures” were injected in a running buffer containing 1
mM Mn2 over the surface for 120 s, and the dissociation phase was
followed for 180 s. Antibodies used are a, JB1 (anti-1, non-functional); b,
11 (anti-5, non-functional); c, no mAb; d, 13 (anti-1, inhibitory); e, SG/19
(anti-1, inhibitory); f, P1D6 (anti-5, inhibitory); and g, 16 (anti-5, in-
hibitory). The concentration of the analytes was 20 nM, and the free mAb
concentration (in Fab equivalent) during the injection was 140 nM.
Preventing the Swing-out of the Integrin Hybrid Domain 27469
show similar binding and inhibition characteristics and have
an overlapping binding footprint, suggesting that the allosteric
mode of inhibition is shared among these three mAbs. In fact,
mAb 13 has been reported to be an allosteric inhibitor for
ligand binding by 51 (11). This notion was based on the fact
that mAb 13 binding to 1 was attenuated by ligand, and the
concentration of ligand required for half-maximal inhibition
was independent of the mAb concentration. Not only occupa-
tion by ligand but also mutations that lock the 1 integrin in a
high affinity state perturb mAb 13 binding (Fig. 2B and Ref.
32), supporting the indirect mode of inhibition by this class of
mAbs. EM images of the integrin-SG/19 Fab complex clearly
show that the mAb docks at the outer hinge connecting the
I-like domain and the hybrid domain. This would prevent the
outward swing of the hybrid domain and fix the closed confor-
mation of the headpiece that represents the low affinity state
(5). Recently, we (33) and others (32) have reported that shape
shifting in the 7 helix region of the  I-like domain up-
regulates ligand affinity. In the context of the whole molecule,
this shape shifting causes an outward swing of the  hybrid
domain (3, 5, 26). Thus inhibitory mAbs represented by mAb 13
and SG/19 exert their effect by disabling the conformational
transition of  I-like domain to the high affinity state. This is
exactly the reverse of the mechanism by which the glycan-
wedge mutation activates integrins (31). It is not clear whether
all anti-1 inhibitory mAbs work with a similar indirect mech-
anism. The inhibitory mAb 4B4 maps to Lys218 of the 1 I-like
domain and does not compete with mAb 13, SG/19, or SG/7.2
The Lys218 epitope of 4B4 is more proximal to the ligand bind-
ing site (Fig. 1). However, because 4B4 binding is also dimin-
ished in the 1 wedge mutant (data not shown), it is likely that
inhibition by 4B4 is, at least in part, allosteric in nature.
Is the allosteric mode specific to 1 mAb or shared with
inhibitory mAb to other integrin  subunits? Inhibitory mAbs
to human 2 are divided into two classes based on the epitope
location, one has been mapped to the top of the I-like domain
primarily recognizing Glu175 or Arg122 and the other recognizes
a combinatorial epitope involving the side chains of Lys133,
His322, and Tyr339 (34). Homology modeling of the 2 I-like
domain reveals that the latter residues are situated on the
side/bottom face of the I-like domain in a location similar to the
epitope residues for mAb 13, SG/19, or SG/7, suggesting the
latter class of mAbs to inhibit 2 integrin function in a way
similar to the mAbs described in this paper. All of the anti-3
inhibitory mAbs in which the epitopes have been mapped in
detail to date recognize the top part of the I-like domain (35),
and it is not known whether these mAbs inhibit 3 integrin
function directly or indirectly. Inspection of the 3 integrin
structure reveals that human/mouse species-specific residues
are excluded from the outer hinge region between the I-like and
hybrid domains, suggesting that mouse anti-human allosteric
inhibitory mAbs against 3 similar to SG/19 could not be ob-
tained because of the sequence conservation.
Mould et al. (10) have reported that anti-5 mAbs also pri-
marily work as allosteric inhibitors. This notion was again
based on the fact that the binding of inhibitory anti-5 mAbs
were non-competitively attenuated by the bound ligand. How-
ever, our SPR experiments clearly showed that 51 bound by
anti-5 mAb 16 or P1D6 had no detectable affinity for ligand, in
contrast to the decreased but significant ligand affinity of the
SG/19-bound form (Fig. 4). This strongly suggests that the
mechanisms for the inhibition are quite different between
these two classes of mAbs. EM imaging of the complex of
Fn7–10 with the 51 headpiece fragment revealed that the
10th module docked onto the / interface with the 7–9th
modules located close to the 5 subunit, although a direct
interaction between the 9th module and the 5 -propeller
domain was not evident (Fig. 3B and Ref. 24). It is therefore
possible that binding of anti-5 mAbs to the top of the 5
-propeller sterically precludes the approach of the Fn7–9 por-
tion, even if the binding site is distinct from the ligand binding
pocket.
The present study underscores the strength of EM imaging
in analyzing the conformation of protein complexes. The deter-
mination of epitope residues by mutagenesis, combined with
three-dimensional structure information, generally leads to a
reasonable assumption about the binding mode of an antibody.
Direct visualization of the antigen-antibody complex, however,
reveals not only the location of the actual interface but also
elucidates the impact of antibody binding on the conformation
of the target protein. In contrast to x-ray crystal structures,
which usually show one of several possible low energy confor-
mations, molecular EM samples the entire set of conformations
of single particles and can thus produce structures for all of the
major conformations present in the protein population. An-
other advantage is that EM imaging can be accomplished with
a relatively small amount of dilute sample.
In conclusion, we have shown that one class of allosteric
anti-1 mAbs blocks ligand binding by preventing the “swing-
out” of the hybrid domain from the I-like domain, thus stabi-
lizing the closed conformation of the integrin headpiece. There
may exist another class of allosterically inhibitory mAbs that
stabilize the “bent” conformation of integrins by stabilizing the
head-tail or -tail--tail interactions. The use of mAbs as a
probe for integrin structure and function has yielded a pro-
found understanding of the mechanisms underlying ligand rec-
ognition and affinity regulation of integrins. The unique mode
of functional perturbation by anti-1 integrin mAbs described
here may have important implications in developing anti-inte-
grin pharmaceuticals. For example, an antibody that stabilizes
the low affinity conformation of an integrin without completely
eliminating its function may prove desirable to prevent the
oversuppression of integrin activity. Stabilizing the natural low
affinity conformation may also be advantageous, because an
antagonist-induced conformational change has been implicated
in the development of autoantibodies in patients receiving anti-
integrin drugs (36).
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